Skip to main content

Table 6 Cox multivariate regression model. (A) metastatic gastric cancer patients. (B) Non-metastatic gastric cancer patients

From: A randomized, double-blind, placebo-controlled investigation of BCc1 nanomedicine effect on survival and quality of life in metastatic and non-metastatic gastric cancer patients

Variables in the equation

 

B

df

Sig.

Exp(B)

95.0% CI

Lower

Upper

(A) Cox multivariate regression model for metastatic gastric cancer

BCc1 nanomedicine indicator

− 0.743

1

0.039

0.476

0.235

0.962

Chemotherapy indicator

− 0.306

1

0.388

0.737

0.368

1.474

(B) Cox multivariate regression model for non-metastatic gastric cancer

BCc1 nanomedicine indicator

− 1.316

1

0.057

0.268

0.069

1.042

Chemotherapy-indicator

0.401

1

0.535

1.494

0.420

5.315